Whelan v. Merrell-Dow Pharmaceuticals, Inc.

117 F.R.D. 299, 1987 U.S. Dist. LEXIS 13050
CourtDistrict Court, District of Columbia
DecidedFebruary 13, 1987
DocketCiv. A. No. 83-3108
StatusPublished

This text of 117 F.R.D. 299 (Whelan v. Merrell-Dow Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Whelan v. Merrell-Dow Pharmaceuticals, Inc., 117 F.R.D. 299, 1987 U.S. Dist. LEXIS 13050 (D.D.C. 1987).

Opinion

MEMORANDUM OPINION and ORDER

ARTHUR L. BURNETT, Sr., United States Magistrate.

Before the United States Magistrate are several motions dealing with discovery and pretrial issues. The Magistrate has now reviewed the entire court file and in order to furnish definitive directions to counsel for the completion of discovery, the Magistrate will proceed to deal with the principal motions in this memorandum opinion.

One of the principal problems concerning the scope of pretrial discovery in this case arises out of the fact that this ease was one of the cases consolidated for pretrial discovery purposes in the multidistrict litigation in the U.S. District Court of Ohio known as In Re: Richardson-Merrell Inc. “Bendectin” Products Liability Litigation (No. II), 606 F.Supp. 715 (Jud.Pan.Mult.Lit.1985). In connection with the cases being remanded back to the transferor courts for further proceedings, Chief Judge Carl B. Rubin of the Southern District of Ohio, who had presided over the [300]*300consolidated multidistrict pretrial proceedings, entered a “Stipulation Status Report” Order on June 10, 1985, the relevant portions of which were:

2. During the three year period that the Bendectin multidistrict cases were pending before this Court, a lead counsel committee selected by the plaintiffs conducted discovery from defendant Merrell Dow Pharmaceuticals Inc. regarding the common issues of causation and liability. The discovery conducted by the Plaintiffs Lead Counsel Committee was on behalf of and applicable to all cases in the multidistrict litigation.
* * * * * *
4. In addition to the discovery regarding the common issues of liability and causation conducted by the plaintiffs against Merrell Dow, Merrell Dow conducted a limited amount of discovery against the individual plaintiffs which was unique to a particular case.1

A common issues trial was held in the Ohio District Court for the Ohio plaintiffs and those who “opted in” to that proceeding. Those cases in which the plaintiffs did not “opt in” were the ones remanded back to the transferor courts, and as to those cases, the Stipulated Status Report Order provided:

9. The cases which are being remanded to the transferor courts are those which did not' “opt-in” to the common issues trial. Discovery from Merrell Dow in these cases as to the common issues is complete. Such discovery from Merrell Dow has not, however, been generally made available to the individual plaintiffs’ counsel, although procedures are being developed to do so. ...
10. In many cases discovery is not complete as to individual aspects of the case, particularly the discovery by Merrell Dow of the plaintiffs’ medical background, family history, damages and medical experts. The principal reason for any such incomplete discovery as to individual issues is that the Court stayed discovery by Merrell Dow for approximately a year in order to facilitate the settlement proceedings and the common issues trial preparation. ...

Counsel for the plaintiffs on August 11, 1986 filed a motion styled, “Plaintiffs’ Motion to Sustain and Affirm All Pretrial Orders Relating to Discovery Remanded Back from the MDL Pretrial Consolidated Proceedings.” Counsel correctly observed that the purpose of multidistrict pretrial proceedings is to consolidate cases to prevent duplication of discovery, avoid inconsistent pretrial rulings and to conserve and economize judicial effort, citing In re Data General Corporation Antitrust Litigation, 470 F.Supp. 855, 858 (Jud.Pan.Mult.Lit.1979). Efficiency and economy of resources are also achieved by eliminating the need to repeatedly depose and re-depose the same experts. See In re Upjohn Co. Antibiotic Cleocin Products, 81 F.R.D. 482, 483-84 (E.D.Mich.1979). The problem in this case is first determining exactly what pretrial rulings were made which govern this case, and what discovery was conducted as to common issues, as the Clerk’s office here has advised that it did not receive all of the referenced documents back from the Southern District of Ohio on discovery and pretrial matters.2 It would thus be imprudent to either grant or deny the Motion as presented to the court in such a “broad brush” manner.

However, from a review of the court file the Magistrate is prepared to make the following rulings. First, all discovery had, and pretrial rulings made as to discovery from Merrell Dow in the multidistrict litigation on Bendectin, shall be fully applicable to this case. As the Court [301]*301there stated in its Stipulated Status Report Order, all discovery from Merrell Dow as to common issues was complete. Thus Merrell Dow is deemed to have fully complied with its obligations in answering interrogatories, producing documents and records, and in furnishing corporate representatives for depositions as to the general issues concerning the manufacturing, advertising, marketing and testing of Bendectin and what it knew concerning whether Bendectin was capable of causing in humans limb deformities and other physiological impairments. Second, the Magistrate concludes that all discovery had of plaintiffs’ experts, in general, as to whether Bendectin was capable of causing limb deformities and physical impairments in fetuses, shall be deemed applicable to this case, and depositions of these experts need not be repeated, and indeed, their videotaped depositions shall be usable in this case if the purpose of multidistrict pretrial proceedings is to be achieved. See In re Upjohn Co. Antibiotic Cleocin Products, supra. Thus, subject to a particular motion in limine by the defendant to preclude the use of a particular videotape deposition of an expert given in the MDL proceeding, the videotape depositions as to the character and composition of, Bendectin and its teratogenic qualities, in general, may be used by the plaintiff in this case to the extent that the deposition testimony is relevant to the issues in this case. In all other respects, plaintiffs’ motion to sustain and affirm all pretrial orders relating to discovery remanded back from the MDL pretrial consolidated proceedings, filed August 11, 1986, is DENIED without prejudice to renew as to particular discovery or a specific pretrial ruling in the multidistrict proceeding relevant to preparation for the formal pretrial conference in this case, arriving at stipulated facts for the trial of this case, or as evidence to be admitted at the trial of this case.

It appears that the principal problem in this case concerning the scope of discovery has been plaintiffs’ counsel’s perception of what were the “common issues” in the case and the meaning and scope of the language “individual aspects of the case, particularly the discovery by Merrell Dow of the plaintiffs’ medical background, family history, damages and medical experts”, the latter providing for the scope of discovery allowable upon return of the cases to the transferor courts.3 As the Magistrate views the record in this case the common issues dealt with the general question of whether Bendectin was capable of causing limb or other physical birth defects in babies in útero and whether this could be established by a preponderance of the evidence. If that general question were answered in the affirmative, there would still be the further question as to whether in this particular case as to the plaintiff, Joseph F.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Data General Corp. Antitrust Litigation
470 F. Supp. 855 (Judicial Panel on Multidistrict Litigation, 1979)
Richardson v. Richardson-Merrell, Inc.
649 F. Supp. 799 (District of Columbia, 1986)
In Re Richardson-Merrell, Inc.
606 F. Supp. 715 (Judicial Panel on Multidistrict Litigation, 1985)
In re Richardson-Merrell, Inc.
97 F.R.D. 481 (S.D. Ohio, 1983)
Duncan v. WJLA-TV, Inc.
106 F.R.D. 4 (District of Columbia, 1984)
Foster v. Michelin Tire Corp.
108 F.R.D. 412 (C.D. Illinois, 1985)
Perkinson v. Houlihan's/D.C., Inc.
110 F.R.D. 55 (District of Columbia, 1986)

Cite This Page — Counsel Stack

Bluebook (online)
117 F.R.D. 299, 1987 U.S. Dist. LEXIS 13050, Counsel Stack Legal Research, https://law.counselstack.com/opinion/whelan-v-merrell-dow-pharmaceuticals-inc-dcd-1987.